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Abstract
The purpose of this study is to determine the correlation between use of antimicrobials, such
as fluoroquinolone, cefoxitin, and cefotaxime, and Escherichia coli resistance using a
nationwide database. Nationwide data on antimicrobial consumption for 12 years (2002 to
2013) were acquired from a database of subjects (n = 1,025,340) included in the National
Health Insurance Service-National Sample Cohort. National antimicrobial resistance rates
of E. coli were obtained from the Korean Antimicrobial Resistance Monitoring System,
which has been administered by the Korean Centers for Disease Control and Prevention
since 2002. Fluoroquinolone-resistance rates of E. coli isolated from general hospitals have
continuously increased since 2002 and were correlated with nationwide fluoroquinolone use
(r = 0.82, P = 0.0012) or ciprofloxacin use (r = 0.90, P<0.0001). Cefotaxime-resistance rates
of E. coli isolated from general hospitals markedly increased since 2008 and were correlated
with nationwide cefotaxime use (r = 0.94, P<0.0001) or third-generation cephalosporin use
(r = 0.96, P<0.0001). Cefoxitin-resistance rates of E. coli isolated from general hospitals
peaked in 2010 and significantly correlated with cephamycin use at a two-year interval (r =
0.64, P = 0.0256). In conclusion, consumption of antimicrobials such as fluoroquinolone,
cefoxitin, and cefotaxime is well correlated with the resistance rates of E. coli to these
agents. This study provides background data for national antimicrobial management poli-
cies to reduce antimicrobial resistance.
Introduction
Appropriate antimicrobial use is essential to control the development of microbial resistance.
Higher rates of resistance have been reported in high antimicrobial consuming countries [1].
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The volumes of antimicrobials used, along with the spread of resistant micro-organisms and
genes encoding for resistance, are known to drive antimicrobial resistance. Although antimi-
crobial use and resistance rates are clearly related [2–4], correlation is not always obvious
because of the complexity of resistance ecology [5–7]. Antimicrobial use and resistance rates
are not perfectly correlated at national levels or across countries because resistance is affected
by several factors, such as the proportion of individuals exposed, the proportion of children in
the population, population density, the effects of different drug classes, and differences
between bacterial species [8].
Because antimicrobial selective pressures differ among countries not only due to different
resistance rates, but also because of discrepancies in medical systems, economic status, and
sociological backgrounds, there is a need to investigate the correlation between antimicrobial
use and resistance in each unique situation. Although associations between antimicrobial resis-
tance and antimicrobial use according to geographic difference have been reported [1,4], stud-
ies on association between antimicrobial resistance and changes in antimicrobial use for long
periods are scarce.
Antimicrobial resistance in South Korea is higher than in advanced regions such as the
United States and Europe [9–11]. In South Korea, it is easy to obtain medical service since
national health insurance for all populations started in 1989, and more antimicrobials are used
than in the United States or Europe because prescription practices in clinics are not strictly
regulated [12,13].
In our 12-year ecological study using a nationwide surveillance and antimicrobial prescrip-
tion database, we investigated the correlation between changes in use of third-generation cepha-
losporin, cephamycin, and fluoroquinolone and Escherichia coli resistance rates. We focused on
E. coli because the wide spread multidrug-resistant E. coli in community and healthcare facilities
has become a serious situation in South Korea [14]. We hope this study will provide background
data for the management of national antimicrobial use to reduce antimicrobial resistance.
Materials and methods
Ethics statement
The study was approved by National Health Insurance Service Ilsan Hospital IRB (NHIMC
2017-03-027). All methods were performed in accordance with the relevant guidelines and reg-
ulations. This study used National Health Insurance Service-National Sample Cohort with per-
mission (REQ0000007624).
Study population
Antimicrobial use in South Korea for 12 years (2002 to 2013) was acquired from a database of
subjects from the National Health Insurance Service-National Sample Cohort (NHIS-NSC), a
population-based cohort established to provide public health researchers and policy makers
with representative, useful information regarding citizens’ utilization of health insurance and
health examinations [15]. Informed consent for study participation was exempted according
to local institutional review board policy. These data consist of a national sample of 1,025,340
people (male: 513,258, female: 512,082) which account for 2.2% of the total South Korean pop-
ulation as of the 2002 census.
Nationwide antimicrobial consumption data
After separation of dispensing and prescribing function policy has been compelled by law in
2000 and all antimicrobials should be used by prescriptions which is electronically transferred
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to national health insurance service and accumulated in systemic database in South Korea
[16]. Therefore, the data precisely reflect the entire use of antibiotics in South Korea. Systemic
antimicrobial prescriptions based on the Anatomical Therapeutic Chemical Classification Sys-
tem (ATC) were included in this study, and amount of use was standardized by Daily Defined
Dose (DDD) by expressing data in DDD per 1000 inhabitants daily (DID). This describes the
number of people (per a population of 1,000) who use an antimicrobial every day and is an
easy way to standardize antimicrobial use, considering dose, form, and frequency of use across
antimicrobial products. Ten DID signifies that 1% of the population, on average, might receive
a certain drug or group of drugs daily. Antimicrobial use by active ingredient (DDD/1,000
inhabitants/day, DID) can be calculated by following equation [17].
Amount of antimicrobials used for a year ðmgÞ
DDD ðmgÞ � 365 days� sample population of the year
� 1; 000 inhabitants
National antimicrobial resistance data
The data of antimicrobial resistance rates in South Korea were obtained from the Korean Anti-
microbial Resistance Monitoring System [14], which has been performed by Korean Centers
for Disease Control and Prevention since 2002. These data were obtained from non-duplicated
clinical isolates in more than 100 bed-sized general hospitals distributed over all regions of
South Korea. Antimicrobial susceptibility tests were done with disk diffusion method or auto-
mated minimal inhibition concentration methods. The results were interpreted according to
Clinical and Laboratory Standard Institute guidelines [18]
Statistical analysis
SAS software, version 9.2 was used for the statistical analysis (SAS Institute, Cary, NC, USA).
The correlations between antimicrobial use and resistance were evaluated by correlation analy-
sis, and a p value less than 0.05 was regarded as significant.
Results
Correlation between fluoroquinolone use and resistance rates to
fluoroquinolone in Escherichia coli
Total fluoroquinolone prescriptions in South Korea increased from 1.445 DID in 2002 to
2.565 DID in 2013. Ciprofloxacin prescriptions in South Korea increased from 0.191 DID in
2002 to 0.675 DID in 2013. Fluoroquinolone-resistance rates of E. coli isolated from general
hospitals has continuously increased from 30% in 2002 to 42.1% in 2013 and nationwide fluo-
roquinolone use increased from 1.445 DID in 2002 to 2.565 DID in 2013. Fluoroquinolone-
resistance rates of E. coli correlated with nationwide total fluoroquinolone use (r = 0.82,
P = 0.0012) and ciprofloxacin use (r = 0.90, P<0.0001, Fig 1).
Correlation between third- and fourth-generation cephalosporin and
fluoroquinolone use and resistance rate to cefotaxime in Escherichia coli
Total third-generation cephalosporin prescriptions in South Korea increased from 0.338 DID
in 2002 to 1.457 DID in 2013. Cefotaxime prescriptions in South Korea increased from 0.020
DID in 2002 to 0.053 DID in 2013. Total fourth-generation cephalosporin prescriptions in
South Korea increased from 0.002 DID in 2002 to 0.046 DID in 2013. Cefotaxime-resistance
rate of E. coli isolated from general hospitals has continuously increased from 10% in 2004 to
28.7% in 2013. Cefotaxime-resistance rate correlated with nationwide third-generation cepha-
losporin use (r = 0.96, P<0.0001) and cefotaxime use (r = 0.94, P<0.0001). Cefotaxime-
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resistance rate of E. coli also correlated with summation of nationwide third- and fourth-gen-
eration cephalosporin use (r = 0.99, P<0.0001, Fig 2).
Correlation between cephamycin use and resistance rates to cefoxitin in
Escherichia coli
Total cephamycin use was 0.027 DID in 2002 and peaked at 0.071 DID in 2007. After 2007,
cephamycin use decreased to 0.046 DID in 2013. Cefoxitin use was 0.003 DID in 2002 and
increased to 0.010 DID in 2008. After 2008, cefoxitin use decreased to 0.008 DID in 2013.
Cefoxitin-resistance rates of E. coli isolated from general hospitals peaked in 2010. This did not
correlate with nationwide cephamycin use (r = 0.61, P = 0.0600), but significantly correlated
with cephamycin use at a two-year interval (r = 0.64, P = 0.0256, Fig 3A and 3B). Cefoxitin-
resistance rate of E. coli correlated with nationwide cefoxitin use (r = 0.73, P = 0.0158, Fig 3C).
The correlation between cephamycin use and the resistance rate to
cefoxitin in Escherichia coli
Total cephamycin use was 0.027 DID in 2002, and peaked to 0.071 DID in 2007. After 2007,
cephamycin use decreased to 0.046 DID in 2013. Cefoxitin use was 0.003 DID in 2002, and
increased to 0.010 DID in 2008. After 2008, cefoxitin use decreased to 0.008 DID in 2013.
Cefoxitin-resistance rates of E. coli isolated from general hospitals have peaked in 2010 and
decreased after that, which did not correlate with nationwide cephamycin use (r = 0.61, P =
0.0600), but significantly correlated with cephamycin use at 2 year interval (r = 0.64, P =
0.0256, Fig 3A and 3B). Cefoxitin-resistance rates of E. coli correlated with nationwide cefoxi-
tin use (r = 0.73, P = 0.0158, Fig 3C).
Discussion
We identified significant correlations between third-generation cephalosporin, cephamycin,
and fluoroquinolone use and E. coli resistance in a 12-year ecological study using nationwide
surveillance and an antimicrobial prescription database.
Fig 1. Correlation of nationwide fluoroquinolone use and resistance rates to fluoroquinolone of Escherichia coli (FQN-R-ECO), isolated from general hospitals
from 2002 to 2013. (A) Correlation of total fluoroquinolone use and rates of FQN-R-ECO (Correlation coefficient r = 0.82, P = 0.0012); (B) Correlation of ciprofloxacin
use and rates of FQN-R-ECO (Correlation coefficient r = 0.90, P<0.0001).
https://doi.org/10.1371/journal.pone.0209580.g001
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Previous antimicrobial exposure is a well-known risk factor for infection with ESBL- or
AmpC-producing E. coli regardless of healthcare-associated or community-associated infec-
tions [19–21]. Single center or multicenter studies of correlation between antimicrobial con-
sumption and resistance rates at the facility level could reflect selections of resistant organisms
or acquisition of resistant genes in normal colonizers under antimicrobial pressure [22,23].
This data can be used as a background for antimicrobial stewardship programs to reduce
unnecessary antimicrobial use and enhance appropriate treatment [24]. The spread of major
antimicrobial-resistant pathogens to the community is an emerging problem [25–30], and all
antimicrobial use, both in healthcare facilities and the community, contributes to enhance-
ment of resistance [23].
Resistance to third-generation cephalosporins such as cefotaxime or ceftazidime via
extended-spectrum β-lactamase (ESBL)-producing E. coli has been widespread in hospitals
around the world since the late 1980s [31], but a sudden worldwide increase in the mid-2000s
as mainly due to sequence type (ST) 131 with resistance to fluoroquinolone and third-
Fig 2. Correlation of nationwide cephalosporin/fluoroquinolone use and resistance rate to cefotaxime of Escherichia coli (CTX-R-ECO), isolated from general
hospitals from 2002 to 2013. (A) Correlation of total third-generation cephalosporin use and rate of CTX-R-ECO (Correlation coefficient r = 0.96, P<0.0001); (B)
Correlation of cefotaxime use and rate of CTX-R-ECO (Correlation coefficient r = 0.94, P<0.0001); (C) Correlation of total third- plus fourth-generation cephalosporin
use and rate of CTX-R-ECO (Correlation coefficient r = 0.99, P<0.0001).
https://doi.org/10.1371/journal.pone.0209580.g002
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generation cephalosporin with CTX-M–type ESBLs [32,33]. A recent study of molecular epi-
demiology showed that H30Rx subsets within the ST131-O25-H30 subclone were associated
specifically with fluoroquinolone resistance, and CTX-M-15 was widely detected in South
Korea [34], the spread of which is an important mechanism of E. coli resistance. E. coli is a
major pathogen involved in urinary tract infection and shows good clinical outcomes [20,35].
However, severe life-threating infections, such as community-onset bacteremia by ESBL-pro-
ducing E. coli, have increased in South Korea, becoming a concerning problem [34,36,37].
It is well-known that a single ST131 strain rapidly expanded and disseminated in most cur-
rent fluoroquinolone-resistant E. coli clinical isolates, which shares ESBL and mutations within
the fluoroquinolone resistance-determining regions of gyrA and parC [38]. Therefore, co-
selection of third-generation cephalosporin and fluoroquinolone may contribute to the
increase in fluoroquinolone and cefotaxime resistance. Cephamycin is not a substrate of ESBL,
and resistance to cefoxitin is mediated with AmpC β-lactamase, which results from overex-
pression of the chromosomal AmpC gene or acquisition of plasmid-mediated AmpC
Fig 3. Correlation of nationwide cephamycin use and resistance rate to cefoxitin of Escherichia coli (FQX-R-ECO), isolated from general hospitals from 2002 to
2013. (A) Correlation of total cephamycin use and rate of FOX-R-ECO (Correlation coefficient r = -0.61, P = 0.0600); (B) Correlation of total cephamycin use and rate
of FOX-R-ECO at two-year intervals (Correlation coefficient r = 0.64, P = 0.0256); (C) Correlation of cefoxitin use and rate of FOX-R-ECO (Correlation coefficient
r = 0.73, P = 0.0158).
https://doi.org/10.1371/journal.pone.0209580.g003
Correlation of antimicrobial use and resistance rates of E. coli
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(pAmpC) determinant [39]. Since Klebsiella pneumoniae with transferrable pAmpC genes was
first detected in South Korea in 1988 [40], pAmpC β-lactamase-producing E. coli with cefoxi-
tin resistance has increased in South Korea [41].
Cefoxitin-resistance rates of E. coli isolated from general hospitals have markedly decreased
since 2011 in South Korea, regardless of clinical breakpoint changes in CLSI guidelines 2010/
2011 [42]. In this study, cefoxitin use decreased after 2008, but resistance rates of E. coli to
cefoxitin did not decrease until 2011. Cefoxitin-resistance rates of E. coli did not significantly
correlate with nationwide cephamycin use (r = -0.61, P = 0.0600), but showed significant cor-
relation with nationwide cephamycin use (r = -0.64, P = 0.0256) at a two-year interval.
Although the time lag between antibiotic consumption and changes in resistance patterns
on a national level is unknown, a period of one to two years has been suggested by other eco-
logic studies [1,4,43]. We suspect that response to cephamycin antibiotic pressure requires one
to two years to influence cephamycin resistance rates, in accordance with previous studies
[1,4,43].
The strong point of this study is analysis based on nationwide surveillance and an antimi-
crobial prescription database over a long period. Although associations between antimicrobial
resistance and antimicrobial use according to geographic difference have been reported several
times [1,4], studies about association between antimicrobial resistance and changes of antimi-
crobial usage for long periods are scarce. National Health Insurance Service (NHIS), a single-
insurer system by the government of South Korea, maintains and stores all national records
for healthcare utilization and prescriptions. NHIS developed the ‘National Health Information
Database’ (NHID) for academic interests, containing personal information, demographics,
and medical treatment data for South Korean citizens, which was generated using participants’
medical bill expenses claimed by medical service providers [15]. We used NHIS-NSC, a repre-
sentative sample database by NHIS with a substantial volume of representative information,
which provided large-scale, extensive, stable nationwide antimicrobial prescription data. This
nationwide study does have a weak point in the significance of relatedness between antimicro-
bial consumption and resistance. But ecologically speaking, the density of antimicrobial usage
involves the total amount of antimicrobial applied to a geographically defined number of indi-
viduals in any setting. Although this study has a less-defined study group compared to a case-
control study, it can initiate a strategy of nationwide antimicrobial control in an evidence-
based way.
In conclusion, correlations between use of antimicrobials such as fluoroquinolone, cefoxi-
tin, and cefotaxime and E. coli resistance to these agents were observed in this study. This pro-
vides background data for national antimicrobial management policies to reduce
antimicrobial resistance.
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